These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36490302)

  • 1. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
    von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
    Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
    Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
    Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
    Sekayan T; Simmons DH; von Drygalski A
    Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
    Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
    N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
    Castaman G; Coppens M; Pipe SW
    Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
    Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
    Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
    Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
    J Manag Care Spec Pharm; 2024 Aug; 30(8):805-816. PubMed ID: 38625717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etranacogene dezaparvovec for hemophilia B gene therapy.
    Thornburg CD
    Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
    Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
    Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etranacogene Dezaparvovec: First Approval.
    Heo YA
    Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
    Miesbach W; Meijer K; Coppens M; Kampmann P; Klamroth R; Schutgens R; Tangelder M; Castaman G; Schwäble J; Bonig H; Seifried E; Cattaneo F; Meyer C; Leebeek FWG
    Blood; 2018 Mar; 131(9):1022-1031. PubMed ID: 29246900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
    Xue F; Li H; Wu X; Liu W; Zhang F; Tang D; Chen Y; Wang W; Chi Y; Zheng J; Du Z; Jiang W; Zhong C; Wei J; Zhu P; Fu R; Liu X; Chen L; Pei X; Sun J; Cheng T; Yang R; Xiao X; Zhang L
    Lancet Haematol; 2022 Jul; 9(7):e504-e513. PubMed ID: 35598604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec.
    Anguela XM; High KA
    Blood Adv; 2024 Apr; 8(7):1796-1803. PubMed ID: 38592711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
    Konkle BA; Walsh CE; Escobar MA; Josephson NC; Young G; von Drygalski A; McPhee SWJ; Samulski RJ; Bilic I; de la Rosa M; Reipert BM; Rottensteiner H; Scheiflinger F; Chapin JC; Ewenstein B; Monahan PE
    Blood; 2021 Feb; 137(6):763-774. PubMed ID: 33067633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
    Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
    J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
    Itzler R; Buckner TW; Leebeek FWG; Miller J; Recht M; Drelich D; Monahan PE; Pipe SW
    Haemophilia; 2024 May; 30(3):709-719. PubMed ID: 38462823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia Gene Therapy: The End of the Beginning?
    De Wolf D; Singh K; Chuah MK; VandenDriessche T
    Hum Gene Ther; 2023 Sep; 34(17-18):782-792. PubMed ID: 37672530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.